Rational design of Gi-biased CB1 agonists, LZD503 & LZD505, reduces side effects, advancing non-opioid therapies and targeting therapeutic efficacy in pain relief. PMID:41980782, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00287-4 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00287-4No description availablewww.cell.com